## SWK Holdings Corporation Increases Revolving Credit Facility to \$60 Million

DALLAS, Oct. 11, 2023 /<u>PRNewswire</u>/ -- <u>SWK Holdings Corporation</u> (Nasdaq: SWKH) ("SWK" or the "Company"), a life-science-focused, specialty finance company catering to small- and mid-sized commercial-stage companies, today announced an amendment to its revolving credit facility. The amended credit facility provides total commitments of \$60 million, including a new \$15 million commitment from Woodforest National Bank ("Woodforest") and an existing \$45 million commitment from First Horizon Bank. All other terms of the facility remain unchanged, including the accordion feature, which provides for expansion of the facility up to \$125 million, subject to customary conditions.

"We are thrilled to partner with Woodforest to expand our credit facility," stated Jody Staggs, President and CEO of SWK Holdings. "In conjunction with the recent closing of a \$30 million senior notes offering, the additional \$15 million of credit facility commitment from Woodforest provides significant capital with which to execute our business plan, providing flexible financing to innovative life science companies."

## About SWK Holdings Corporation

SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and midsized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from \$5.0 million to \$25.0 million. SWK also owns Enteris BioPharma, a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform. Additional information on the life science finance market is available on the Company's website at <u>www.swkhold.com</u>.

## Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors which, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

## SOURCE SWK Holdings Corporation

For further information: Tiberend Strategic Advisors, Inc., Daniel Kontoh-Boateng (Investors), dboateng@tiberend.com; or Jason Rando (Media), jrando@tiberend.com

https://swkhold.investorroom.com/2023-10-11-SWK-Holdings-Corporation-Increases-Revolving-Credit-Facility-to-60-Million